Mostrar el registro sencillo del ítem

dc.contributor.authorMarcink, T C
dc.contributor.authorYariv, E
dc.contributor.authorRybkina, K
dc.contributor.authorMas-Lloret, Vicente 
dc.contributor.authorBovier, F T
dc.contributor.authordes Georges, A
dc.contributor.authorGreninger, A L
dc.contributor.authorAlabi, C A
dc.contributor.authorPorotto, M
dc.contributor.authorBen-Tal, N
dc.contributor.authorMoscona, A
dc.date.accessioned2020-02-19T08:15:24Z
dc.date.available2020-02-19T08:15:24Z
dc.date.issued2020-02-11
dc.identifier.citationmBio. 2020 Feb 11;11(1). pii: e03203-19.es_ES
dc.identifier.issn2150-7511es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/9110
dc.description.abstractThe receptor binding protein of parainfluenza virus, hemagglutinin-neuraminidase (HN), is responsible for actively triggering the viral fusion protein (F) to undergo a conformational change leading to insertion into the target cell and fusion of the virus with the target cell membrane. For proper viral entry to occur, this process must occur when HN is engaged with host cell receptors at the cell surface. It is possible to interfere with this process through premature activation of the F protein, distant from the target cell receptor. Conformational changes in the F protein and adoption of the postfusion form of the protein prior to receptor engagement of HN at the host cell membrane inactivate the virus. We previously identified small molecules that interact with HN and induce it to activate F in an untimely fashion, validating a new antiviral strategy. To obtain highly active pretriggering candidate molecules we carried out a virtual modeling screen for molecules that interact with sialic acid binding site II on HN, which we propose to be the site responsible for activating F. To directly assess the mechanism of action of one such highly effective new premature activating compound, PAC-3066, we use cryo-electron tomography on authentic intact viral particles for the first time to examine the effects of PAC-3066 treatment on the conformation of the viral F protein. We present the first direct observation of the conformational rearrangement induced in the viral F protein.IMPORTANCE Paramyxoviruses, including human parainfluenza virus type 3, are internalized into host cells by fusion between viral and target cell membranes. The receptor binding protein, hemagglutinin-neuraminidase (HN), upon binding to its cell receptor, triggers conformational changes in the fusion protein (F). This action of HN activates F to reach its fusion-competent state. Using small molecules that interact with HN, we can induce the premature activation of F and inactivate the virus. To obtain highly active pretriggering compounds, we carried out a virtual modeling screen for molecules that interact with a sialic acid binding site on HN that we propose to be the site involved in activating F. We use cryo-electron tomography of authentic intact viral particles for the first time to directly assess the mechanism of action of this treatment on the conformation of the viral F protein and present the first direct observation of the induced conformational rearrangement in the viral F protein.es_ES
dc.description.sponsorshipThis work was supported by National Institute of Allergy and Infectious Diseases (NIAID), NIH, grants R01AI031971 and R01AI114736 to A.M. and by USA-Israel Binational Science Foundation (BSF) grant 2017293 to N.B.-T. E.Y. was partially funded by a fellowship from the Edmond J. Safra Center for Bioinformatics at Tel Aviv University. N.B.-T.’s research is supported in part by the Abraham E. Kazan Chair in Structural Biology, Tel Aviv University.es_ES
dc.language.isoenges_ES
dc.publisherAmerican Society for Microbiology (ASM) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAntiviral agentses_ES
dc.subjectCryo-electron tomographyes_ES
dc.subjectViral fusion proteines_ES
dc.subjectViral protein structurees_ES
dc.subjectViral receptores_ES
dc.titleHijacking the Fusion Complex of Human Parainfluenza Virus as an Antiviral Strategyes_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID32047132es_ES
dc.format.volume11es_ES
dc.format.number1es_ES
dc.identifier.doi10.1128/mBio.03203-19es_ES
dc.contributor.funderNIH - National Institute of Allergy and Infectious Diseases (NIAID) (Estados Unidos) 
dc.description.peerreviewedes_ES
dc.identifier.e-issn2150-7511es_ES
dc.relation.publisherversionhttps://doi.org/10.1128/mBio.03203-19es_ES
dc.identifier.journalmBioes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/R01AI031971es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/R01AI114736es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/2017293es_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional